Paul M. Barr

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 13 papers. Top paper: “Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial”.

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood(2022)10.1182/blood.2021014960

N/A

5.5DataRank · unranked

240 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +17 more

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102959

N/A

0.465DataRank · unranked

9 citations

Michael T. Brady, Myla Strawderman, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen +13 more

Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8038

N/A

0DataRank · unranked

1 citations

Jun Yin, Levi Pederson, Betsy LaPlant, Mazyar Shadman, Hongli Li +15 more

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Blood(2021)10.1182/blood.2021011841

N/A

0DataRank · unranked

70 citations

Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids +47 more

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood(2021)10.1182/blood.2020010146

N/A

0DataRank · unranked

35 citations

Curtis A. Hanson, Renee C. Tschumper, Connie Lesnick, Esteban Braggio, Elisabeth Paietta +17 more

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Haematologica(2022)10.3324/haematol.2021.279560

N/A

0DataRank · unranked

4 citations

Sara K. Blick-Nitko, Andrea Baran, Derick R. Peterson, Hannah E. Whitehead, Raquel Izumi +7 more

Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

Leukemia Research(2023)10.1016/j.leukres.2023.107072

N/A

0DataRank · unranked

7 citations

Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea Baran +8 more

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Blood(2023)10.1182/blood-2023-187128

N/A

0DataRank · unranked

39 citations

William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan +6 more

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Blood Advances(2025)10.1182/bloodadvances.2024013474

N/A

0DataRank · unranked

6 citations

Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos +16 more

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

Nature Communications(2025)10.1038/s41467-025-64666-7

N/A

0DataRank · unranked

2 citations

Roshia Ali, Alyssa Bouska, Dylan T. Jochum, Meghana Kesireddy, Simeon Mahov +34 more

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Blood(2020)10.1182/blood.2020006965

N/A

0DataRank · unranked

318 citations

Lindsey E. Roeker, Nicole Lamanna, John N. Allan, Lori A. Leslie, John M. Pagel +57 more

233 | S1608: RANDOMIZED PHASE II TRIAL COMPARING LENALIDOMIDE/OBINUTUZUMAB AND UMBRALISIB/OBINUTUZUMAB WITH CHEMOIMMUNOTHERAPY IN EARLY PROGRESSING FOLLICULAR LYMPHOMA (POD24)

Hematological Oncology(2025)10.1002/hon.70094_233

N/A

0DataRank · unranked

0 citations

H. Li, Heiko Schöder, Alex F. Herrera, Richard Burack, Brian K. Link +10 more

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3815

N/A

0DataRank · unranked

116 citations

Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander +49 more